Answers are grounded in this paper and cite their sources.
Gene therapy in patients with severe sickle cell disease has been recently approved for commercial use, even in children. Clinical trials leading to approval were limited to patients with hemoglobin SS and Sβ 0 , due to the severity of disease in these patients. The efficacy of gene therapy in patients with hemoglobin SC disease is unknown. We provide details on treatment and clinical course of the first hemoglobin SC patient treated with gene therapy due to the severity of symptoms and the absence of any viable treatment options that could provide relief from the ravages of the disease.
No takes yet. Share an insight, caveat, or question.
Laditan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: